GEN News Highlights

Minnesota Partnership Dedicates Genomics Facility

(Page
1
of
1)

As a result of a $21.7 million bonding issue approved by the Minnesota Legislature, a new genomics research facility has been dedicated at the Vincent Stabile Building in Rochester. The three-story addition to the building includes genomic laboratories, facilities for bioinformatics, and conference and meeting rooms that will support ongoing research by the Minnesota Partnership for Biotechnology and Medical Genomics.

The Minnesota Partnership is a collaborative venture among the Mayo Clinic, University of Minnesota, and State of Minnesota. On December 14, 2006, the University of Minnesota purchased the 12th and 13th floor Partnership research space in the Stabile Building and leased it back to Mayo Clinic.

"This facility offers Minnesota Partnership researchers the laboratory support and technology needed to speed research aimed at major diseases affecting the people of the state," says Glenn Forbes, M.D., CEO of Mayo Clinic, Rochester.

The facility will house approximately 300 researchers. "The kind of space we are providing to researchers in the Stabile Building will help us to attract top talent and research dollars for the Partnership and it will serve as a catalyst for other bioscience development in Minnesota," says Frank Cerra, senior vp for Health Sciences, University of Minnesota.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.